{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T16:24:47Z","timestamp":1773419087461,"version":"3.50.1"},"reference-count":48,"publisher":"Elsevier BV","content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Brain Research"],"published-print":{"date-parts":[[2013,8]]},"DOI":"10.1016\/j.brainres.2013.06.034","type":"journal-article","created":{"date-parts":[[2013,7,4]],"date-time":"2013-07-04T08:23:10Z","timestamp":1372926190000},"page":"238-245","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"special_numbering":"C","title":["Central administration of an orexin receptor 1 antagonist prevents the stimulatory effect of Olanzapine on endogenous glucose production"],"prefix":"10.1016","volume":"1527","author":[{"given":"Elodie M.","family":"Girault","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ewout","family":"Foppen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mari\u00ebtte T.","family":"Ackermans","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eric","family":"Fliers","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andries","family":"Kalsbeek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.brainres.2013.06.034_bib1","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1210\/jc.86.5.2220","article-title":"The quantification of gluconeogenesis in healthy men by (2)H2O and [2-(13)C]glycerol yields different results: rates of gluconeogenesis in healthy men measured with (2)H2O are higher than those measured with [2-(13)C]glycerol","volume":"86","author":"Ackermans","year":"2001","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.brainres.2013.06.034_bib2","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1097\/MPA.0b013e3181f74b4b","article-title":"Mechanism of orexin B-stimulated insulin and glucagon release from the pancreas of normal and diabetic rats","volume":"40","author":"Adeghate","year":"2011","journal-title":"Pancreas"},{"key":"10.1016\/j.brainres.2013.06.034_bib3","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1038\/oby.2006.6","article-title":"Hormonal and metabolic effects of olanzapine and clozapine related to body weight in rodents","volume":"14","author":"Albaugh","year":"2006","journal-title":"Obesity (Silver Spring)"},{"key":"10.1016\/j.brainres.2013.06.034_bib4","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.ejphar.2008.06.105","article-title":"The antipsychotics clozapine and olanzapine increase plasma glucose and corticosterone levels in rats: comparison with aripiprazole, ziprasidone, bifeprunox and F15063","volume":"592","author":"Assie","year":"2008","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.brainres.2013.06.034_bib5","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1097\/YIC.0b013e3283377850","article-title":"Plasma orexin A, ghrelin, cholecystokinin, visfatin, leptin and agouti-related protein levels during 6-week olanzapine treatment in first-episode male patients with psychosis","volume":"25","author":"Basoglu","year":"2010","journal-title":"Int. Clin. Psychopharmacol."},{"key":"10.1016\/j.brainres.2013.06.034_bib6","doi-asserted-by":"crossref","first-page":"110140","DOI":"10.1503\/jpn.110140","article-title":"Differential effects of 3 classes of antidiabetic drugs on olanzapine-induced glucose dysregulation and insulin resistance in female rats","volume":"37","author":"Boyda","year":"2012","journal-title":"J. Psychiatry Neurosci."},{"key":"10.1016\/j.brainres.2013.06.034_bib7","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1016\/j.neuropharm.2011.02.019","article-title":"Intermittent treatment with olanzapine causes sensitization of the metabolic side-effects in rats","volume":"62","author":"Boyda","year":"2012","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.brainres.2013.06.034_bib8","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1002\/1096-9861(20010319)431:4<405::AID-CNE1079>3.0.CO;2-D","article-title":"Parasympathetic and sympathetic control of the pancreas: a role for the suprachiasmatic nucleus and other hypothalamic centers that are involved in the regulation of food intake","volume":"431","author":"Buijs","year":"2001","journal-title":"J. Comp. Neurol."},{"key":"10.1016\/j.brainres.2013.06.034_bib9","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.schres.2008.12.012","article-title":"Insulin resistance and secretion in vivo: effects of different antipsychotics in an animal model","volume":"108","author":"Chintoh","year":"2009","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.brainres.2013.06.034_bib10","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1097\/JCP.0b013e318184b4c5","article-title":"Insulin resistance and decreased glucose-stimulated insulin secretion after acute olanzapine administration","volume":"28","author":"Chintoh","year":"2008","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.brainres.2013.06.034_bib11","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/s00213-005-0279-x","article-title":"The atypical antipsychotics olanzapine and quetiapine, but not haloperidol, reduce ACTH and cortisol secretion in healthy subjects","volume":"185","author":"Cohrs","year":"2006","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.brainres.2013.06.034_bib12","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1097\/00006676-200308000-00009","article-title":"Effects of ghrelin and other neuropeptides (CART, MCH, orexin A and B, and GLP-1) on the release of insulin from isolated rat islets","volume":"27","author":"Colombo","year":"2003","journal-title":"Pancreas"},{"key":"10.1016\/j.brainres.2013.06.034_bib13","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1073\/pnas.96.2.748","article-title":"Orexins, orexigenic hypothalamic peptides, interact with autonomic, neuroendocrine and neuroregulatory systems","volume":"96","author":"Date","year":"1999","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.brainres.2013.06.034_bib14","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1007\/s00213-008-1415-1","article-title":"Hyperphagia and increased meal size are responsible for weight gain in rats treated sub-chronically with olanzapine","volume":"203","author":"Davoodi","year":"2009","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.brainres.2013.06.034_bib15","doi-asserted-by":"crossref","first-page":"6742","DOI":"10.1523\/JNEUROSCI.22-15-06742.2002","article-title":"Differential activation of orexin neurons by antipsychotic drugs associated with weight gain","volume":"22","author":"Fadel","year":"2002","journal-title":"J. Neurosci."},{"key":"10.1016\/j.brainres.2013.06.034_bib16","doi-asserted-by":"crossref","first-page":"e20571","DOI":"10.1371\/journal.pone.0020571","article-title":"Olanzapine-induced hyperphagia and weight gain associate with orexigenic hypothalamic neuropeptide signaling without concomitant AMPK phosphorylation","volume":"6","author":"Ferno","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.brainres.2013.06.034_bib17","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.cmet.2008.10.010","article-title":"Enhanced orexin receptor-2 signaling prevents diet-induced obesity and improves leptin sensitivity","volume":"9","author":"Funato","year":"2009","journal-title":"Cell Metab."},{"key":"10.1016\/j.brainres.2013.06.034_bib18","doi-asserted-by":"crossref","first-page":"e43244","DOI":"10.1371\/journal.pone.0043244","article-title":"Acute peripheral but not central administration of olanzapine induces hyperglycaemia associated with hepatic and extra-hepatic insulin resistance","volume":"7","author":"Girault","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.brainres.2013.06.034_bib19","doi-asserted-by":"crossref","first-page":"10911","DOI":"10.1073\/pnas.96.19.10911","article-title":"Orexin A activates locus coeruleus cell firing and increases arousal in the rat","volume":"96","author":"Hagan","year":"1999","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.brainres.2013.06.034_bib20","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1038\/sj.npp.1301209","article-title":"Acute effects of atypical antipsychotics on whole-body insulin resistance in rats: implications for adverse metabolic effects","volume":"32","author":"Houseknecht","year":"2007","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.brainres.2013.06.034_bib21","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/S0304-3940(00)01498-1","article-title":"Both corticotropin releasing factor and neuropeptide Y are involved in the effect of orexin (hypocretin) on the food intake in rats","volume":"293","author":"Ida","year":"2000","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.brainres.2013.06.034_bib22","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1046\/j.1365-2826.2000.00572.x","article-title":"Effects of orexins on the hypothalamic\u2013pituitary\u2013adrenal system","volume":"12","author":"Jaszberenyi","year":"2000","journal-title":"J. Neuroendocrinol."},{"key":"10.1016\/j.brainres.2013.06.034_bib23","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1007\/s002130000551","article-title":"Effects of centrally administered orexin-B and orexin-A: a role for orexin-1 receptors in orexin-B-induced hyperactivity","volume":"153","author":"Jones","year":"2001","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.brainres.2013.06.034_bib24","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.neuron.2008.06.012","article-title":"A role for brain stress systems in addiction","volume":"59","author":"Koob","year":"2008","journal-title":"Neuron"},{"key":"10.1016\/j.brainres.2013.06.034_bib25","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1055\/s-0031-1301365","article-title":"Insulin secretion and sensitivity after single-dose amisulpride, olanzapine or placebo in young male subjects: double blind, cross-over glucose clamp study","volume":"45","author":"Kopf","year":"2012","journal-title":"Pharmacopsychiatry"},{"key":"10.1016\/j.brainres.2013.06.034_bib26","doi-asserted-by":"crossref","first-page":"1977","DOI":"10.1097\/00001756-200006260-00034","article-title":"Centrally administered orexin\/hypocretin activates HPA axis in rats","volume":"11","author":"Kuru","year":"2000","journal-title":"Neuroreport"},{"key":"10.1016\/j.brainres.2013.06.034_bib27","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1002\/cne.1190","article-title":"Differential expression of orexin receptors 1 and 2 in the rat brain","volume":"435","author":"Marcus","year":"2001","journal-title":"J. Comp. Neurol."},{"key":"10.1016\/j.brainres.2013.06.034_bib28","first-page":"428","article-title":"Effect of antipsychotic-induced hyperprolactinemia on anthropometric measures, insulin sensitivity and lipid profile in patients with schizophrenia or related psychoses","volume":"32","author":"Melkersson","year":"2011","journal-title":"Neuroendocrinol. Lett."},{"key":"10.1016\/j.brainres.2013.06.034_bib29","doi-asserted-by":"crossref","first-page":"742","DOI":"10.4088\/JCP.v61n1006","article-title":"Elevated levels of insulin, leptin, and blood lipids in olanzapine-treated patients with schizophrenia or related psychoses","volume":"61","author":"Melkersson","year":"2000","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.brainres.2013.06.034_bib30","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.peptides.2007.10.016","article-title":"Olanzapine blocks the sympathetic and hyperthermic reactions due to cerebral injection of orexin A","volume":"29","author":"Monda","year":"2008","journal-title":"Peptides"},{"key":"10.1016\/j.brainres.2013.06.034_bib31","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/S0024-3205(99)00611-6","article-title":"Acute orexin effects on insulin secretion in the rat: in vivo and in vitro studies","volume":"66","author":"Nowak","year":"2000","journal-title":"Life Sci."},{"key":"10.1016\/j.brainres.2013.06.034_bib32","first-page":"969","article-title":"Evidence that orexins A and B stimulate insulin secretion from rat pancreatic islets via both receptor subtypes","volume":"15","author":"Nowak","year":"2005","journal-title":"Int. J. Mol. Med."},{"key":"10.1016\/j.brainres.2013.06.034_bib33","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1007\/s00213-012-2850-6","article-title":"Comparison of metabolic effects of ziprasidone versus olanzapine treatment in patients with first-episode schizophrenia","volume":"225","author":"Ou","year":"2012","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.brainres.2013.06.034_bib34","first-page":"133","article-title":"Orexins, a novel family of hypothalamic neuropeptides, modulate pituitary luteinizing hormone secretion in an ovarian steroid-dependent manner","volume":"78","author":"Pu","year":"1998","journal-title":"Regul. Pept."},{"key":"10.1016\/j.brainres.2013.06.034_bib35","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1093\/schbul\/sbm087","article-title":"The orexin-1 antagonist SB-334867 blocks antipsychotic treatment emergent catalepsy: implications for the treatment of extrapyramidal symptoms","volume":"33","author":"Rasmussen","year":"2007","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.brainres.2013.06.034_bib36","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1038\/sj.npp.1301239","article-title":"The orexin-1 receptor antagonist SB-334867 blocks the effects of antipsychotics on the activity of A9 and A10 dopamine neurons: implications for antipsychotic therapy","volume":"32","author":"Rasmussen","year":"2007","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.brainres.2013.06.034_bib37","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1046\/j.1365-2826.2001.00672.x","article-title":"The central effects of orexin-A in the hypothalamic-pituitary-adrenal axis in vivo and in vitro in male rats","volume":"13","author":"Russell","year":"2001","journal-title":"J. Neuroendocrinol."},{"key":"10.1016\/j.brainres.2013.06.034_bib38","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1038\/sj.npp.1301541","article-title":"Effects of olanzapine and ziprasidone on glucose tolerance in healthy volunteers","volume":"33","author":"Sacher","year":"2008","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.brainres.2013.06.034_bib39","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.smrv.2004.07.007","article-title":"Roles of orexin\/hypocretin in regulation of sleep\/wakefulness and energy homeostasis","volume":"9","author":"Sakurai","year":"2005","journal-title":"Sleep Med. Rev."},{"key":"10.1016\/j.brainres.2013.06.034_bib40","doi-asserted-by":"crossref","first-page":"R382","DOI":"10.1152\/ajpregu.00496.2006","article-title":"Hypocretin\/orexin type 1 receptor in brain: role in cardiovascular control and the neuroendocrine response to immobilization stress","volume":"292","author":"Samson","year":"2007","journal-title":"Am. J. Physiol. Regul. Integr. Comp. Physiol."},{"key":"10.1016\/j.brainres.2013.06.034_bib41","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/j.cmet.2009.09.013","article-title":"Hypothalamic orexin stimulates feeding-associated glucose utilization in skeletal muscle via sympathetic nervous system","volume":"10","author":"Shiuchi","year":"2009","journal-title":"Cell Metab."},{"key":"10.1016\/j.brainres.2013.06.034_bib42","doi-asserted-by":"crossref","first-page":"241","DOI":"10.3109\/13813455.2011.576681","article-title":"Olanzapine effects on body composition, food preference, glucose metabolism and insulin sensitivity in the rat","volume":"117","author":"Smith","year":"2011","journal-title":"Arch. Physiol. Biochem."},{"key":"10.1016\/j.brainres.2013.06.034_bib43","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1111\/j.1749-6632.1959.tb44923.x","article-title":"Influences of glucose loading and of injected insulin on hepatic glucose output","volume":"82","author":"Steele","year":"1959","journal-title":"Ann. N.Y. Acad. Sci."},{"key":"10.1016\/j.brainres.2013.06.034_bib44","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1038\/oby.2008.468","article-title":"The role of thermogenesis in antipsychotic drug-induced weight gain","volume":"17","author":"Stefanidis","year":"2009","journal-title":"Obesity (Silver Spring)"},{"key":"10.1016\/j.brainres.2013.06.034_bib45","doi-asserted-by":"crossref","first-page":"2922","DOI":"10.1038\/npp.2008.9","article-title":"Zonisamide prevents olanzapine-associated hyperphagia, weight gain, and elevated blood glucose in rats","volume":"33","author":"Wallingford","year":"2008","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.brainres.2013.06.034_bib46","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/j.euroneuro.2011.09.003","article-title":"Effects of olanzapine on muscarinic M3 receptor binding density in the brain relates to weight gain, plasma insulin and metabolic hormone levels","volume":"22","author":"Weston-Green","year":"2012","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.brainres.2013.06.034_bib47","doi-asserted-by":"crossref","first-page":"11439","DOI":"10.1523\/JNEUROSCI.3459-04.2004","article-title":"Interaction between the corticotropin-releasing factor system and hypocretins (orexins): a novel circuit mediating stress response","volume":"24","author":"Winsky-Sommerer","year":"2004","journal-title":"J. Neurosci."},{"key":"10.1016\/j.brainres.2013.06.034_bib48","doi-asserted-by":"crossref","first-page":"1998","DOI":"10.2337\/db09-0385","article-title":"A major role for perifornical orexin neurons in the control of glucose metabolism in rats","volume":"58","author":"Yi","year":"2009","journal-title":"Diabetes"}],"container-title":["Brain Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006899313009207?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006899313009207?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,7,17]],"date-time":"2019-07-17T00:07:40Z","timestamp":1563322060000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006899313009207"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,8]]},"references-count":48,"alternative-id":["S0006899313009207"],"URL":"https:\/\/doi.org\/10.1016\/j.brainres.2013.06.034","relation":{},"ISSN":["0006-8993"],"issn-type":[{"value":"0006-8993","type":"print"}],"subject":[],"published":{"date-parts":[[2013,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Central administration of an orexin receptor 1 antagonist prevents the stimulatory effect of Olanzapine on endogenous glucose production","name":"articletitle","label":"Article Title"},{"value":"Brain Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.brainres.2013.06.034","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}